Nigeria’s TB response at a crossroads as new vaccines approach
Nigeria’s battle against tuberculosis could benefit significantly from the development of next-generation vaccines, but the prospect of new prevention tools raises an important public health question: will scientific advances translate into affordable and accessible protection for Nigerians living at risk of the disease?
The global TB response is entering a potentially significant period, with new vaccines projected to become available from 2029, subject to clinical trial results and regulatory approval.
Gavi, the Vaccine Alliance, estimates that these vaccines could save 7.3 million lives by 2050 and generate up to $135 billion in economic benefits for low- and middle-income countries.
For Nigeria, where TB prevention and treatment remain important public health priorities, the projected gains could be substantial.
Yet the availability of a vaccine alone would not eliminate the disease. The effectiveness of the national response would continue to depend on early diagnosis, treatment, contact tracing, preventive therapy and public awareness.
A Century-Old Vaccine and the Search for Better Protection
The development of new TB vaccines comes against the backdrop of a long-standing gap in disease prevention. The Bacille Calmette-Guérin (BCG) vaccine remains the only licensed TB vaccine, despite more than a century of research into improved prevention methods.
While BCG provides protection against severe forms of TB in children, its effectiveness against pulmonary TB in adolescents and adults is limited. This has intensified the search for vaccines capable of preventing infection and disease among older age groups.
READ ALSO; From COVID vaccines to Neuralink: Inside Dr. Stella Immanuel’s population-control warning
The World Health Organization (WHO) has identified the development of effective TB vaccines for adolescents and adults as a major research priority. However, promising candidates must still demonstrate safety and efficacy before they can be approved for widespread use.
The 7.3 Million-Lives Projection
Gavi’s reported projection of 7.3 million lives saved by 2050 presents a potentially transformative opportunity for countries with high TB burdens. The estimated economic gains of up to $135 billion could result from fewer illnesses, reduced healthcare expenditure and improved productivity.
But these figures are projections, not guaranteed outcomes.
Their realisation will depend on several factors, including the effectiveness of the vaccines, the speed of regulatory approvals, manufacturing capacity, affordability and the ability of national health systems to deliver vaccination to vulnerable populations.
The question facing policymakers is whether financial and logistical barriers could prevent low- and middle-income countries from benefiting fully from the anticipated scientific advances.
Nigeria’s Preparedness Under Scrutiny
For Nigeria, the arrival of next-generation TB vaccines would raise questions about the country’s readiness to incorporate new prevention tools into its existing healthcare system.
Key issues include the financing of vaccine procurement, the availability of cold-chain infrastructure, healthcare-worker capacity, public acceptance and the identification of populations that would benefit most from vaccination.
A successful vaccination programme would also need to complement, rather than replace, existing TB control measures. People with suspected TB would still require timely testing, while those diagnosed with the disease would need access to effective treatment.
Contact tracing and preventive therapy would remain important for reducing transmission and protecting individuals at increased risk.
Several TB vaccine candidates are undergoing clinical development, including M72/AS01E and MTBVAC. Their progress has generated interest in the possibility of more effective protection against TB, particularly among adolescents and adults.
READ ALSO; Senate hearing set to review research on COVID-19 vaccines, cancer concerns
However, the eventual availability of these vaccines depends on the evidence generated through clinical trials, regulatory decisions and the ability of manufacturers to produce them at scale.
The anticipated 2029 timeframe should therefore be understood as a potential milestone rather than a guaranteed date for widespread access in Nigeria.
For African countries, introducing a new vaccine would require more than international approval. Governments would need to assess their disease burden, determine vaccination priorities, mobilise financing and establish systems capable of delivering the vaccines safely and equitably.
International health organisations, donors and vaccine manufacturers would also have a role in addressing supply constraints and affordability.
Without adequate preparation, countries with substantial TB burdens could face delays between the licensing of a vaccine and its actual availability to those who need it.
Tuberculosis remains a major global health challenge, particularly in low- and middle-income countries. New vaccines could strengthen prevention efforts, but their impact would depend on how effectively they are integrated into broader disease-control programmes.
For Nigeria, the coming years will be crucial for assessing the potential role of next-generation vaccines, the resources required for introduction and the measures needed to ensure that existing TB services remain effective.
The projected 7.3 million lives saved and $135 billion in economic benefits illustrate the potential scale of the opportunity.
The unresolved issue is whether the global health community can turn those projections into measurable improvements in the lives of people affected by tuberculosis.